Peptide database

Essential redox cofactor and sirtuin/PARP substrate whose restoration is studied for mitochondrial and metabolic aging.

CNTF-derived peptidergic compound that promotes neurogenesis and reduces tau pathology in preclinical Alzheimer's models.

Endogenous cyclic peptide that inhibits GH, insulin, glucagon, and gastric secretion via SSTR1-5 receptors.

Nonapeptide posterior pituitary hormone driving uterine contraction and milk letdown; studied intranasally for social cognition.

28-aa neuropeptide acting on VPAC1/2 receptors; vasodilatory, bronchodilatory, and anti-inflammatory.

Endogenous 28-aa 'hunger hormone' from the stomach; activates GHS-R1a to stimulate GH release and appetite.

Long-acting somatostatin analog that inhibits GH, glucagon, and gut hormone secretion; used for acromegaly and neuroendocrine tumors.

Once-daily acylated GLP-1 receptor agonist for type 2 diabetes and chronic weight management.

Long-acting GLP-1 receptor agonist that improves glycemic control, slows gastric emptying, and reduces appetite.

Selective V2-receptor vasopressin analog that concentrates urine; used for diabetes insipidus, nocturnal enuresis, and bleeding disorders.

38-aa neuropeptide of the VIP/secretin family acting on PAC1 receptors; neuroprotective and vasoregulatory.

Recombinant PTH(1-34) that, given intermittently, stimulates osteoblastic bone formation; approved for severe osteoporosis.

Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.

Human cathelicidin antimicrobial peptide with broad-spectrum antibacterial, immunomodulatory, and wound-healing activity.

GnRH agonist that suppresses gonadotropin and sex-steroid production after initial stimulation; used in prostate cancer, endometriosis, and precocious puberty.

Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.

33-aa hypothalamic neuropeptide acting on OX1/OX2 receptors to promote wakefulness and arousal.

Once-weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended half-life.

Depot somatostatin analog inhibiting GH/IGF-1 and neuroendocrine secretion; approved for acromegaly and GEP-NETs.

Long-acting GnRH agonist that after initial flare downregulates pituitary receptors, suppressing sex hormones for prostate cancer and endometriosis.

36-aa HIV gp41 fusion inhibitor that blocks viral entry into CD4 cells; first-in-class antiretroviral fusion inhibitor.

Selective bradykinin B2 receptor antagonist decapeptide approved for acute attacks of hereditary angioedema.

Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.

First-generation ghrelin receptor agonist hexapeptide that stimulates GH release and strongly increases appetite.

Porcine brain-derived peptide preparation with neurotrophic-factor-like activity studied in stroke, TBI, and dementia.

28-aa thymic peptide that enhances T-cell maturation and TLR signaling; approved in many countries for hepatitis and as an immune adjuvant.

43-aa actin-sequestering peptide that drives cell migration, angiogenesis, and repair in cardiac, corneal, and dermal tissue.

Mitochondrial-derived 24-aa peptide with cytoprotective, anti-apoptotic, and insulin-sensitizing effects in aging and neurodegeneration models.

Guanylate cyclase-C agonist 14-aa peptide that increases intestinal fluid secretion and transit; approved for IBS-C and chronic constipation.

Amylin analog adjunct to insulin that slows gastric emptying, suppresses glucagon, and increases satiety.

PTHrP(1-34) analog that selectively favors bone anabolism with less hypercalcemia than teriparatide; approved for osteoporosis.

Zinc-dependent thymic nonapeptide that regulates T-cell differentiation and has analgesic and anti-inflammatory effects.

GLP-2 receptor agonist that promotes intestinal mucosal growth and absorption; approved for short bowel syndrome.

KISS1R agonist decapeptide that triggers hypothalamic GnRH release, upstream regulator of reproductive hormone axis.

Synthetic GnRH decapeptide that stimulates pituitary LH and FSH release; used diagnostically and to support gonadal function.

Potent GHRP-family ghrelin receptor agonist with studied cardioprotective effects independent of GH release.

NCAM-derived FG-loop peptide that activates FGFR1 to enhance synaptic plasticity and memory in animal models.

Mitochondrial-derived 16-aa peptide that activates AMPK and improves insulin sensitivity and metabolic homeostasis.

Mitochondria-targeting tetrapeptide that binds cardiolipin on the inner membrane to stabilize cristae and restore ATP production.

Gastric-juice-derived pentadecapeptide that promotes angiogenesis (VEGF) and tissue repair via FAK-paxillin and NO-system modulation.

ACTH(4-10)-derived heptapeptide that elevates BDNF and modulates the melanocortin system; used clinically in Russia for stroke and cognition.

Synthetic hexapeptide ghrelin receptor agonist that potently stimulates GH secretion; also raises appetite, cortisol, and prolactin.

Bovine cortex-derived polypeptide complex used clinically in Eastern Europe for encephalopathy and cognitive disorders.

Mechanically activated IGF-1 splice variant that activates muscle satellite cells for repair and hypertrophy.

Non-selective melanocortin receptor agonist that stimulates melanogenesis (tanning) and increases libido via MC1R/MC4R.

Triple GIP/GLP-1/glucagon receptor agonist in phase 3 trials showing the largest weight reductions of any incretin therapy to date.

Uroguanylin-analog GC-C agonist that promotes pH-dependent intestinal fluid secretion; approved for chronic idiopathic constipation and IBS-C.

Selective MC1R agonist approved (Scenesse) to prevent phototoxicity in erythropoietic protoporphyria by stimulating eumelanin.

Melanocortin MC4R agonist approved for hypoactive sexual desire disorder; acts centrally to increase sexual arousal.

Stabilized GHRH analog approved for HIV-associated lipodystrophy; reduces visceral adipose tissue via GH/IGF-1 axis stimulation.

Long-acting amylin analog in trials for obesity, including combination with semaglutide (CagriSema).

C-terminal tripeptide of α-MSH with anti-inflammatory action via PepT1 uptake and NF-κB inhibition, studied in IBD models.

Synthetic dipeptide (Glu-Trp) immunomodulator used in Eastern Europe to restore immune balance during infection and immunodeficiency.

Proline-containing dipeptide prodrug of cycloprolylglycine; increases BDNF/NGF expression with nootropic and anxiolytic effects.

8-aa fragment of activity-dependent neuroprotective protein (ADNP) that stabilizes microtubules; trialed in PSP and schizophrenia.

PSD-95 inhibitor peptide that uncouples NMDA-receptor excitotoxic signaling; studied in acute ischemic stroke (ESCAPE-NA1).

Copper-binding tripeptide that stimulates collagen synthesis, wound healing, and remodeling gene expression.

Tuftsin-derived heptapeptide with anxiolytic and nootropic effects via GABAergic modulation and enkephalin stabilization.

Dual glucagon/GLP-1 receptor agonist in phase 3 for obesity and MASH.

Khavinson tetrapeptide reported to activate telomerase and normalize pineal melatonin rhythms in aging models.

Selective ghrelin receptor (GHS-R1a) agonist that stimulates GH release with minimal effect on cortisol or prolactin.

Tight-junction-regulating octapeptide that reduces intestinal permeability ('leaky gut'); trialed as an adjunct for celiac disease.

GLP-1/glucagon dual receptor agonist in late-stage trials for obesity and type 2 diabetes.

Tetrasubstituted GHRH(1-29) analog with improved enzymatic stability that amplifies pulsatile GH secretion.

Orally active ghrelin receptor agonist approved as a diagnostic agent for adult growth hormone deficiency.

Albumin-binding (DAC) GHRH analog producing sustained, multi-day elevation of GH and IGF-1.

Truncated IGF-1 variant with high local potency and short half-life, studied for site-specific muscle growth.

Activin-binding glycoprotein that antagonizes myostatin (GDF-8) to release the brake on skeletal muscle growth.

GHRH(1-29) analog that binds pituitary GHRH receptors to stimulate pulsatile growth hormone release.

Erythropoietin-derived 11-aa peptide targeting the innate repair receptor (EPOR/CD131) for tissue protection without erythropoiesis.

C-terminal fragment of human growth hormone studied for lipolytic activity independent of IGF-1 signaling.

D-retro-inverso peptide that disrupts FOXO4-p53 interaction to selectively trigger apoptosis in senescent cells (senolytic).

Angiotensin IV-derived small peptide that potentiates HGF/c-Met signaling to drive synaptogenesis in preclinical cognition models.

Long-acting IGF-1 analog with reduced IGFBP binding, prolonging activation of the IGF-1 receptor to drive muscle hypertrophy.

Synthetic version of the actin-binding region of thymosin β4; promotes cell migration, angiogenesis, and wound repair.

Single-chain relaxin-2 analog that activates RXFP1 to reduce organ fibrosis without the full hormone's complexity.

Matrikine signal peptide that stimulates collagen I, III, and fibronectin synthesis to reduce wrinkle depth in topical use.

Khavinson bioregulator tripeptide (EDR) proposed to modulate neuronal gene expression and protect against oxidative stress.

Soluble ActRIIB-Fc decoy receptor that sequesters myostatin and related ligands; trialed in muscular dystrophy before discontinuation.

Modified C-terminal hGH fragment designed to stimulate lipolysis without growth-promoting or glycemic effects.

Proapoptotic peptidomimetic that targets the blood supply of white adipose tissue, causing fat reduction in primate studies.

SNARE-mimetic hexapeptide that mildly inhibits catecholamine/acetylcholine release to soften expression lines ('topical Botox').

Orally active non-peptide ghrelin mimetic that sustains elevated GH and IGF-1 levels for 24 hours per dose.

Arginate-salt analog of the BPC-157 sequence marketed for tissue repair; minimal independent published data.

Octapeptide extension of Argireline that competes with SNAP-25 in the SNARE complex to reduce muscle contraction and wrinkles.